Fondaparinux sodium

For patients undergoing major orthopedic surgery and abdominal surgery, venous thromboembolism is one of the most common postoperative complications, and the advent of fondaparinux sodium provides a more accurate anticoagulation option for such high-risk groups. As a synthetic selective factor Xa inhibitor, it specifically binds to antithrombin III to accelerate the inactivation of factor Xa, thereby blocking the coagulation cascade. Compared with unfractionated heparin and low molecular weight heparin, it has lower bleeding risk and fewer drug interactions. Clinically, it is mainly used for the prevention and treatment of deep vein thrombosis of the lower extremities and pulmonary embolism, and can also be combined with antiplatelet drugs for the anticoagulation management of patients with acute coronary syndrome. The applicable population covers high-risk patients after surgery, patients with cardiovascular diseases, and patients receiving treatment for thrombotic diseases.

At present, the global market size of fondaparinux sodium is approximately USD 780 million, and the compound annual growth rate from 2023 to 2028 is expected to remain at 4.2%. The core growth drivers are the increase in the number of surgical procedures and the rising prevalence of cardiovascular diseases. In the domestic market, after the expiration of the original research patent, the generic drug substitution process has continued to accelerate. Seven domestic enterprises have obtained approval for the production of APIs and preparations. Since 2022, the winning bid price in the national centralized drug procurement has decreased by up to 92% compared with the original research drug, and the accessibility in the primary market has been greatly improved, corresponding to a stable annual growth rate of approximately 11% in the demand for upstream APIs.

CATO can provide a full set of impurity reference standards for fondaparinux sodium API. All products meet the quality control requirements of multiple regulatory systems such as the Chinese Pharmacopoeia and FDA. Sufficient spot inventory enables same-day delivery, which can fully meet the impurity research needs of pharmaceutical enterprises throughout the whole cycle from generic drug consistency evaluation to commercial production, helping enterprises shorten the R&D cycle and reduce compliance risks.